Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823459 · ClinicalTrials.gov registry record · Phase 2
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
A Phase 2 study, sponsored by Susan Chang.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT00823459: Completed Phase 2 study, sponsored by Susan Chang.
NCT00823459 is a Phase 2 study that has completed, run by Susan Chang. The registered enrollment target is 58 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00823459, a Phase 2 study, has completed, sponsored by Susan Chang.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Primary Outcome
Number of patients alive without progressive disease at 6 months. Assessment of progression was defined by RANO as a 25% increase in the sum of all the products of measurable lesions, clear worsening of any evaluable disease or any new lesion
Interventions
- DRUG Everolimus
- OTHER Archival Tissue Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2009-01-23 |
| Est. Completion | 2017-11-13 |
| Phase | Phase 2 |
What the finished NCT00823459 record still lists
NCT00823459 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 0 conditions, and to 2 interventions - of which Everolimus is the first listed.
NCT00823459 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00823459 about?
NCT00823459 is a clinical study titled "Everolimus in Treating Patients With Recurrent Low-Grade Glioma". This phase II trial studies how well everolimus works in treating patients with recurrent low-grade glioma. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
What is the current status of trial NCT00823459?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2009-01-23. Estimated completion is 2017-11-13.
What interventions are being tested in trial NCT00823459?
The interventions under investigation include: Everolimus (DRUG), Archival Tissue Analysis (OTHER).
Who is sponsoring clinical trial NCT00823459?
This trial is sponsored by Susan Chang, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00823459's enrollment target sits among peer trials
58 1135th of 2000 higher than 860 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI